Rempex Pharmaceuticals, Inc.

Molsoft LLC

New York University

Melinta Subsidiary Corp.

University of Massachusetts

Icahn School of Medicine at Mount Sinai

Qpex Biopharma, Inc.

Melinta Therapeutics, Inc.

Maxim Totrov

Scott J Hecker

Raja K Reddy

Serge H Boyer

Michael N Dudley

David C Griffith

Gavin C Hirst

Olga Rodny

Tomasz W Glinka

Olga Lomovskaya

Susan Zolla-Pazner

Ruben Abagyan

Timothy J Cardozo

Shan Lu

Xiang-peng Kong

Stephen R Wilson

Abraham Pinter

Herbert H Samuels

Shixia Wang

Bruce M Raaka

Zhiguo Zhou

Miroslaw K Gorny

Xiangpeng Kong

Matthieu Schapira

Li Fan

Eugene Raush

Levon Budagyan

Andrew J W Orry

Ruimin Pan

Xunqing Jiang

Serge Henri Boyer

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives

The present invention relates to isolated immunogenic polypeptides and their use. In one aspect, the isolated immunogenic polypeptide includes a scaffold polypeptide having a hairpin loop modified to include one or more epitopes heterologous to the scaffold polypeptide and from an amino acid loop linked by a disulfide bond. The scaffold polypeptide directs self-assembly with two other of the scaffold polypeptides to form a trimeric structure, which constrains the one or more epitopes to a conformation that is (i) substantially similar to one or more native pathogen epitopes in trimeric conformation and (ii) capable of binding an antibody reactive to the one or more native pathogen epitopes in trimeric conformation. Another aspect relates to an isolated immunogenic polypeptide that includes a scaffold polypeptide having a native loop modified to include one or more epitopes heterologous to the scaffold polypeptide and from an amino acid loop linked by a disulfide bond. The scaffold polypeptide directs self-assembly with four other of said scaffold polypeptides to form a pentameric structure, which constrains the one or more epitopes to a conformation capable of binding an antibody reactive to one or more native pathogen epitopes.

Immunogenic polypeptides

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.

Boronic acid derivatives and therapeutic uses thereof

Pharmaceutical compositions comprising cyclic boronic acid ester derivatives

Cyclic boronic acid ester derivatives and methods of making the same

Cyclic boronic acid ester derivatives and therapeutic uses thereof

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. Other embodiments relate to pharmaceutical compositions containing boronic acid derivatives and additional excipient such as meglumine.

The present invention is directed to a recombinant immunogenic polypeptide. The polypeptide includes a loop peptide inserted into an immunogenic scaffold protein. The loop polypeptide has an amino acid sequence which presents the 3074 mAb- or the 2219/2557 mAb-targeted epitope of the HIV gp120 protein and not other known epitopes of the HIV gp120 protein. When used as an immunogen, the polypeptide induces an antibody response which neutralizes heterologous HIV-1 viruses in a pattern similar to that observed for the 3074 mAb- or the 2219/2557 mAb-targeted epitope, respectively. Pharmaceutical compositions containing the immunogenic polypeptide as well as methods of making and using it are also disclosed.

Immunogenic polypeptides comprising a modified loop peptide presenting the HIV-1 GP120 3074 mAb epitope and scaffold proteins containing said peptide

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to 1 cyclic boronic acid ester derivatives and their use as therapeutic agents.

Growing community of inventors

San Diego, CA, United States of America

Maxim Totrov